Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women
Autore:
Archer, DF;
Indirizzi:
Eastern Virginia Med Sch, Jones Inst Reprod Med, Clin Res Ctr, Norfolk, VA23507 USA Eastern Virginia Med Sch Norfolk VA USA 23507 s Ctr, Norfolk, VA23507 USA Eastern Virginia Med Sch, Jones Inst Reprod Med, Dept Obstet & Gynecol, Norfolk, VA 23507 USA Eastern Virginia Med Sch Norfolk VA USA 23507 ecol, Norfolk, VA 23507 USA
Titolo Testata:
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
fascicolo: 4, volume: 8, anno: 2001,
pagine: 245 - 251
SICI:
1072-3714(200107/08)8:4<245:TEOTDO>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
ESTROGEN REPLACEMENT THERAPY; CONJUGATED ESTROGENS; HORMONE REPLACEMENT; ORAL-CONTRACEPTIVES; EXOGENOUS ESTROGEN; BLEEDING PATTERNS; RISK-FACTORS; HYPERPLASIA; CARCINOMA; METAANALYSIS;
Keywords:
estrogen; progestin; hormone replacement therapy; endometrial cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
58
Recensione:
Indirizzi per estratti:
Indirizzo: Archer, DF Eastern Virginia Med Sch, Jones Inst Reprod Med, Clin Res Ctr, 601 Colley Ave, Norfolk, VA 23507 USA Eastern Virginia Med Sch 601 Colley Ave Norfolk VA USA 23507 SA
Citazione:
D.F. Archer, "The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women", MENOPAUSE, 8(4), 2001, pp. 245-251

Abstract

Objective: Women who have ever used estrogen replacement therapy (ERT), even at a low dose, have an increased incidence of endometrial cancer. The addition of a progestin to ERT reduces the incidence of endometrial cancer. The duration of progestin administration is more important than the dose. Design: A MEDLINE review of the literature was performed using the search terms endometrial cancer, epidemiology, and hormone replacement therapy (HRT). Results: Women who have ever used ERT have an increased incidence of endometrial cancer. The use of HRT for more than 5 years, with a progestin use of < 10 days per cycle, has a relative risk = 1.8. Continuous combined HRT, or sequential or cyclic HRT with > 10 days of progestin per cycle, appears to decrease the incidence of endometrial cancer to that found in nonusers of HRT. Conclusions: The use of HRT in postmenopausal women with a uterus reduces the incidence of endometrial cancer. The duration of progestin administration should be 14 days or more per cycle based on recent epidemiologic data.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 11:27:06